TOKYO —

Consuming too much salt, a ubiquitous component of the modern diet, extends its detrimental influence far beyond elevated blood pressure. Emerging scientific evidence strongly suggests that excessive sodium intake can also significantly impair cognitive functions, including memory and thinking abilities, and negatively impact emotional well-being. While the link between high salt (HS) consumption and hypertension is a well-established public health concern, the potential neurobiological ramifications underscore the urgent need to identify and implement strategies that can effectively mitigate these adverse effects. A recent breakthrough from researchers in Japan offers a promising avenue, highlighting a compound derived from soy, known as LPC70, as a potential protector against the pervasive damage wrought by a high-salt diet (HSD).

Unveiling the Mechanism: How a Soy Compound Intervenes in Salt-Induced Damage

The groundbreaking research, spearheaded by Professor Akihiro Mouri and Dr. Hisayoshi Kubota, with contributions from Dr. Kazuhiro Kagotani, delves into the intricate molecular pathways through which LPC70 exerts its protective effects. Their study, published online on May 14, 2026, and appearing in the July 1, 2026, issue of Neurochemistry International (Volume 197), builds upon prior investigations that indicated LPC70’s ability to ameliorate both high blood pressure and cognitive deficits observed in mice subjected to a HSD. The latest findings provide a crucial mechanistic understanding, revealing that this soy-derived compound actively modulates key chemical signaling processes within the brain and kidneys.

At the heart of this research lies the role of prostaglandins (PGs), a class of signaling molecules synthesized from the fatty acid arachidonic acid (AA). These compounds function akin to localized hormones, orchestrating a myriad of essential physiological processes throughout the body. In the cardiovascular system, prostaglandins are instrumental in regulating blood pressure by influencing the vasodilation and vasoconstriction of blood vessels. Their actions within the brain are notably more complex and context-dependent. Depending on the specific receptors they engage, prostaglandins can either initiate signals that confer neuroprotection or contribute to detrimental pathways that may compromise memory, cognitive acuity, and emotional regulation.

LPC70 is a specific form of soy lysolecithin, characterized by a high concentration of lysophosphatidylcholine (LPC)—accounting for over 70% of its phospholipid content. While earlier studies had demonstrated LPC70’s efficacy in alleviating salt-induced hypertension and cognitive impairments, the precise mechanisms underlying these benefits, particularly its influence on prostaglandin signaling, remained largely elusive.

A Detailed Look at the Experimental Design and Findings

To unravel these mechanisms, Professor Mouri, Dr. Kubota, and their colleagues embarked on a series of experiments using mouse models. Dr. Kubota, the study’s first author, played a pivotal role, meticulously assessing blood pressure, monitoring behavioral changes indicative of cognitive and social function, and conducting detailed analyses of molecular activity related to prostaglandin signaling in both the kidneys and brain. Their collaborative efforts, which involved Dr. Kazuhiro Kagotani of Tsuji Oil Mills Co., Ltd., and the Tsuji Health and Beauty Science Laboratory at Mie University, provided a comprehensive understanding of how LPC70 selectively intervenes in organ-specific responses to excessive salt intake.

The research team’s affiliations highlight the interdisciplinary nature of the project: Professor Mouri and Dr. Kubota are associated with the Department of Regulatory Science for Evaluation and Development of Pharmaceuticals & Devices at Fujita Health University Graduate School of Medical Science, as well as the International Center for Brain Science (ICBS) at Fujita Health University in Japan. This institutional backing provided a robust framework for advanced biomedical research.

The initial observations in the mouse models aligned with expectations: mice fed a high-salt diet exhibited significantly elevated blood pressure. However, the study revealed that the detrimental consequences of excessive sodium extended far beyond the cardiovascular system. The HSD-fed mice displayed a marked reduction in social interaction and struggled with object recognition memory tasks, suggesting a tangible decline in cognitive abilities. Notably, their general locomotor activity and anxiety-like behaviors remained largely unaffected, indicating that high salt intake selectively disrupted more complex cognitive and social functions rather than inducing generalized behavioral impairments.

The introduction of LPC70 into the diets of these mice yielded remarkable improvements. The animals exhibited a significant reduction in blood pressure, and their performance on tests assessing social interaction and object recognition memory improved substantially. These positive behavioral outcomes prompted the researchers to investigate the underlying molecular changes occurring within the kidneys and brain.

Differential Protective Mechanisms in Kidneys and Brain

The investigation into the kidneys revealed that a HSD led to an increased expression of two key players in prostaglandin signaling: cyclooxygenase-2 (COX-2) and the PGE2 receptor EP3. Both of these components are implicated in the development of hypertension associated with high salt intake. Crucially, LPC70 supplementation effectively attenuated these salt-induced increases, suggesting that the compound helps to normalize kidney signaling pathways that are essential for maintaining healthy blood pressure regulation.

In contrast, the brain exhibited a different pattern of response. In the prefrontal cortex, a brain region critically involved in executive functions such as planning, decision-making, memory, and social behavior, excessive salt intake was found to decrease the expression of the PGD2 receptor DP1. This receptor is known to mediate protective and anti-inflammatory signaling within the brain. LPC70 treatment successfully restored the expression of DP1, while importantly, it did not alter the expression of DP2, another receptor associated with potentially detrimental effects on neuronal function. This selective restoration of DP1 signaling is a key finding, implying that LPC70 does not broadly inhibit or stimulate all prostaglandin activity. Instead, it appears to preferentially enhance pathways that confer neuroprotection, thereby explaining the observed improvements in memory and social behavior in the treated mice.

An Unexpected Shift in Arachidonic Acid Metabolism

Adding another layer of complexity to their findings, the research team observed an unexpected alteration in the metabolism of arachidonic acid, the precursor fatty acid for prostaglandins. Mice consuming a HSD exhibited lower levels of circulating arachidonic acid. However, upon administration of LPC70, the levels of prostaglandins derived from arachidonic acid, specifically PGE2 and PGD2, actually increased. This seemingly paradoxical result suggests that under conditions of high salt intake, LPC70 may enhance the body’s efficiency in utilizing the available arachidonic acid to synthesize prostaglandins. This improved utilization could be critical for maintaining adequate levels of protective signaling molecules in the face of salt-induced disruptions.

Collectively, these findings illuminate a sophisticated and highly selective biological response. In the kidneys, LPC70 appears to counteract the signaling alterations that promote hypertension. In the brain, it works to re-establish signaling pathways that are crucial for protecting against inflammation and neuronal damage. The compound’s efficacy, therefore, is not a one-size-fits-all approach but rather a nuanced intervention tailored to the specific physiological context of each organ and the particular prostaglandin receptors involved.

Implications for Public Health and Future Dietary Interventions

The implications of this research are significant, suggesting that LPC70 could eventually be developed as a valuable functional food ingredient. Its demonstrated ability to improve both cardiovascular and cognitive performance in animal models points towards its potential to support overall health, particularly for individuals whose diets are habitually high in sodium. Professor Mouri expressed optimism about the future: "Our study elucidates LPC70’s role in PG signaling, laying the groundwork for future clinical research and dietary interventions aimed at reducing hypertension-related cognitive decline and promoting healthy aging globally."

This work provides a clearer mechanistic understanding of how a soy-derived compound can positively influence the body’s response to excessive salt intake. It opens promising avenues for nutritional strategies aimed at safeguarding long-term health against the pervasive risks associated with high sodium consumption. The research was a collaborative effort, originating from a joint project with Tsuji Oil Mills Co., Ltd., a company dedicated to developing naturally derived food ingredients. This partnership exemplifies how industry and academia can converge to address critical health challenges.

Funding and Support for the Research Endeavor

The scientific exploration was made possible through substantial financial and logistical support from various institutions. Key funding was provided through Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) under grant numbers 20K07931, 22K07606, 22K11891, and 23H02843.

Additional significant support was channeled through the Fujita Mind-Brain Research & Innovation Center for Drug Generation (Fujita Mind-BRIDGe) as part of Japan’s Peak Research Universities (J-PEAKS) Program (JPJS00420240019). The Japan Science and Technology Agency (JST) FOREST Program also contributed funding (JPMJFR215H).

Tsuji Oil Mills Co., Ltd. provided direct financial backing for the research. Further grants and support were furnished by the Education and Research Facility of Animal Models for Human Diseases at Fujita Health University, the Smoking Research Foundation, and the Takeda Science Foundation. This multi-faceted support underscores the collaborative spirit and the recognized importance of this line of inquiry.

The Path Forward: From Lab Bench to Human Trials

While the findings in mice are highly encouraging, it is imperative to acknowledge that these results represent preclinical data. Extensive clinical trials in human populations are essential to confirm whether LPC70 or similar soy-derived compounds can replicate these beneficial effects in humans. Such trials would need to rigorously assess safety, optimal dosage, and long-term efficacy across diverse demographic groups.

The implications for public health policy and dietary recommendations are substantial. If proven effective in humans, LPC70 could become a key component of dietary strategies aimed at mitigating the global burden of cardiovascular disease and cognitive impairment linked to excessive salt intake. The World Health Organization (WHO) recommends a daily sodium intake of less than 2,000 mg (equivalent to less than 5 grams of salt) for adults, yet many populations far exceed this recommendation.

The research published in Neurochemistry International marks a significant step forward in understanding the complex interplay between diet, brain health, and kidney function. It offers a beacon of hope for developing innovative, naturally derived interventions to combat the widespread health consequences of modern dietary habits. As Professor Mouri aptly concluded, this study "lays the groundwork for future clinical research and dietary interventions aimed at reducing hypertension-related cognitive decline and promoting healthy aging globally." The journey from laboratory discovery to widespread clinical application is often long, but this research provides a compelling roadmap for future efforts in nutritional science and preventative medicine.